Shopping Cart 0
Cart Subtotal
USD 0

Oral Mucositis-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Oral Mucositis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis-Pipeline Review, H2 2017, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 5

Global Markets Direct Report Coverage 5

Oral Mucositis-Overview 6

Oral Mucositis-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Oral Mucositis-Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Oral Mucositis-Companies Involved in Therapeutics Development 21

Clevexel Pharma SAS 21

Colby Pharmaceutical Company 21

Galera Therapeutics Inc 22

Humanetics Corp 22

Innovation Pharmaceuticals Inc 23

Onxeo SA 23

Oragenics Inc 24

Otsuka Holdings Co Ltd 24

Soligenix Inc 25

Spectrum Pharmaceuticals Inc 25

Spherium Biomed SL 26

Oral Mucositis-Drug Profiles 27

AG-013-Drug Profile 27

BCD-600-Drug Profile 30

BIO-300-Drug Profile 31

brilacidin tetrahydrochloride-Drug Profile 34

clonidine hydrochloride ER-Drug Profile 46

CVXL-0095-Drug Profile 50

dusquetide-Drug Profile 51

EC-18-Drug Profile 58

GC-4419-Drug Profile 60

Gene Therapy for Oral Mucositis-Drug Profile 63

Gene Therapy to Activate SOD2 for Oral Mucositis-Drug Profile 64

GM-0111-Drug Profile 65

HYLP-006-Drug Profile 67

KIN-219-Drug Profile 68

melatonin-Drug Profile 69

phenylbutyrate-Drug Profile 70

pralatrexate-Drug Profile 71

rebamipide-Drug Profile 77

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders-Drug Profile 79

Oral Mucositis-Dormant Projects 80

Oral Mucositis-Discontinued Products 82

Oral Mucositis-Product Development Milestones 83

Featured News & Press Releases 83

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96


List Of Figure

List of Figures

Number of Products under Development for Oral Mucositis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Oral Mucositis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Oral Mucositis-Pipeline by Clevexel Pharma SAS, H2 2017

Oral Mucositis-Pipeline by Colby Pharmaceutical Company, H2 2017

Oral Mucositis-Pipeline by Galera Therapeutics Inc, H2 2017

Oral Mucositis-Pipeline by Humanetics Corp, H2 2017

Oral Mucositis-Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Oral Mucositis-Pipeline by Onxeo SA, H2 2017

Oral Mucositis-Pipeline by Oragenics Inc, H2 2017

Oral Mucositis-Pipeline by Otsuka Holdings Co Ltd, H2 2017

Oral Mucositis-Pipeline by Soligenix Inc, H2 2017

Oral Mucositis-Pipeline by Spectrum Pharmaceuticals Inc, H2 2017

Oral Mucositis-Pipeline by Spherium Biomed SL, H2 2017

Oral Mucositis-Dormant Projects, H2 2017

Oral Mucositis-Dormant Projects, H2 2017 (Contd..1), H2 2017

Oral Mucositis-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Oral Mucositis Therapeutic Products under Development, Key Players in Oral Mucositis Therapeutics, Oral Mucositis Pipeline Overview, Oral Mucositis Pipeline, Oral Mucositis Pipeline Assessment


Companies

Oral Mucositis Therapeutic Products under Development, Key Players in Oral Mucositis Therapeutics, Oral Mucositis Pipeline Overview, Oral Mucositis Pipeline, Oral Mucositis Pipeline Assessment

Oral Mucositis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis-Pipeline Review, H2 2017, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 5

Global Markets Direct Report Coverage 5

Oral Mucositis-Overview 6

Oral Mucositis-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Oral Mucositis-Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Oral Mucositis-Companies Involved in Therapeutics Development 21

Clevexel Pharma SAS 21

Colby Pharmaceutical Company 21

Galera Therapeutics Inc 22

Humanetics Corp 22

Innovation Pharmaceuticals Inc 23

Onxeo SA 23

Oragenics Inc 24

Otsuka Holdings Co Ltd 24

Soligenix Inc 25

Spectrum Pharmaceuticals Inc 25

Spherium Biomed SL 26

Oral Mucositis-Drug Profiles 27

AG-013-Drug Profile 27

BCD-600-Drug Profile 30

BIO-300-Drug Profile 31

brilacidin tetrahydrochloride-Drug Profile 34

clonidine hydrochloride ER-Drug Profile 46

CVXL-0095-Drug Profile 50

dusquetide-Drug Profile 51

EC-18-Drug Profile 58

GC-4419-Drug Profile 60

Gene Therapy for Oral Mucositis-Drug Profile 63

Gene Therapy to Activate SOD2 for Oral Mucositis-Drug Profile 64

GM-0111-Drug Profile 65

HYLP-006-Drug Profile 67

KIN-219-Drug Profile 68

melatonin-Drug Profile 69

phenylbutyrate-Drug Profile 70

pralatrexate-Drug Profile 71

rebamipide-Drug Profile 77

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders-Drug Profile 79

Oral Mucositis-Dormant Projects 80

Oral Mucositis-Discontinued Products 82

Oral Mucositis-Product Development Milestones 83

Featured News & Press Releases 83

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96


List Of Figure

List of Figures

Number of Products under Development for Oral Mucositis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Oral Mucositis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Oral Mucositis-Pipeline by Clevexel Pharma SAS, H2 2017

Oral Mucositis-Pipeline by Colby Pharmaceutical Company, H2 2017

Oral Mucositis-Pipeline by Galera Therapeutics Inc, H2 2017

Oral Mucositis-Pipeline by Humanetics Corp, H2 2017

Oral Mucositis-Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Oral Mucositis-Pipeline by Onxeo SA, H2 2017

Oral Mucositis-Pipeline by Oragenics Inc, H2 2017

Oral Mucositis-Pipeline by Otsuka Holdings Co Ltd, H2 2017

Oral Mucositis-Pipeline by Soligenix Inc, H2 2017

Oral Mucositis-Pipeline by Spectrum Pharmaceuticals Inc, H2 2017

Oral Mucositis-Pipeline by Spherium Biomed SL, H2 2017

Oral Mucositis-Dormant Projects, H2 2017

Oral Mucositis-Dormant Projects, H2 2017 (Contd..1), H2 2017

Oral Mucositis-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Oral Mucositis Therapeutic Products under Development, Key Players in Oral Mucositis Therapeutics, Oral Mucositis Pipeline Overview, Oral Mucositis Pipeline, Oral Mucositis Pipeline Assessment


Companies

Oral Mucositis Therapeutic Products under Development, Key Players in Oral Mucositis Therapeutics, Oral Mucositis Pipeline Overview, Oral Mucositis Pipeline, Oral Mucositis Pipeline Assessment